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Introduction: Surgical resection is being increasingly used
for early-stage small cell lung cancer (SCLC). However, there
are sparse data regarding the role of adjuvant therapies,
particularly postoperative radiation therapy (PORT). We
investigated the impact of PORT on survival after complete
surgical resection for SCLC using the National Cancer
Database.
Methods: There were 3017 patients diagnosed with non-
metastatic SCLC between 1998 and 2011 who underwent
R0 sublobar resection, lobectomy, or pneumonectomy. Pa-
tients were stratiﬁed by the use of PORT, and only those
who received a minimum dose of 45 Gy were included. The
overall survival (OS) of patients based on PORT use were
analyzed by Kaplan–Meier analysis and compared using the
log-rank test. Multivariate Cox regression analysis was used
to identify factors associated with survival.
Results: For the entire study population, the 5-year OS
was signiﬁcantly poorer with the addition of PORT
(33.9% versus 40.6%; p ¼ 0.005). When analyzed by
subgroup, patients with pN0 stage had signiﬁcantly
decreased OS with PORT (39.3% versus 46.3%; p ¼ 0.07)
and patients with pN2 stage had signiﬁcantly improved
OS with PORT (29.0% versus 18.6%; p < 0.001). No dif-
ferences in OS were observed in patients with pN1 stage.
On multivariate analysis, the hazard ratio for PORT in pN0
disease was 1.36 (95% conﬁdence interval, 1.09–1.70;
p < 0.001) and the hazard ratio for PORT in pN2
disease was 0.60 (95% conﬁdence interval, 0.45–0.80;
p < 0.001).
Conclusion: The use of PORT was associated with a dele-
terious effect on OS in patients with pN0 disease but
signiﬁcantly improved OS in patients with pN2 disease.Journal of Thoracic Oncology Vol. 11 No. 2: 242-248 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Introduction
There are an estimated 221,200 new cases of lung
cancer diagnosed annually in the United States.1
Small cell lung cancer (SCLC) represents approxi-
mately 15% of cases, of which roughly 30% are
nonmetastatic.2 Multimodality therapy is essential in
the management of this disease because of its pro-
pensity for both local and distant progression. Two
phase III trials have failed to show a beneﬁt with the
addition of surgery to multimodality treatment.3,4
However, more recent studies have suggested that
surgical resection may be considered in patients
with early-stage disease.5,6 Consequently, national
guidelines currently support the use of surgical
management for patients with clinical stage T1–2, N0
SCLC.7
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pathologic upstaging after surgery,8 and locoregional
failure remains high even after complete resection.4,8 The
indications for adjuvant postoperative radiation therapy
(PORT) are currently not well-deﬁned because there are
few studies speciﬁcally addressing the issue. A subset
analysis from a Surveillance, Epidemiology, and End Re-
sults (SEER) database study noted a survival beneﬁt
associated with PORT for pN2 disease,5 and a small
retrospective review of patients treated with complete
surgical resection found that PORT signiﬁcantly improved
both locoregional control and overall survival for patients
with pathological node-positive disease.9 Given the
paucity of data in the current literature examining the role
of PORT, we analyzed the National Cancer Database
(NCDB) to determine the impact of PORT on overall sur-
vival (OS) after complete resection of limited-stage SCLC
(LS-SCLC) in a large cohort of patients.
Methods
The NCDB is a joint project of the American Cancer
Society and the Commission on Cancer of the American
College of Surgeons. It is estimated that 70% of all
diagnosed malignancies in the United States are
captured by facilities participating in this registry and
are reported to the NCDB. The Commission on Cancer’s
NCDB and the hospitals participating in the NCDB are the
source of the deidentiﬁed data used in this study.
However, they have not veriﬁed and are not responsible
for the statistical validity or conclusions reached by the
authors of this study. Exemption was obtained from the
New York Harbor Veterans Affairs Committee for
Research and Development before this study began.
Adult patients with nonmetastatic SCLC who were
treated with surgery consisting of sublobar resection,
lobectomy, or pneumonectomy from between 1998 and
2011 were included. All included patients had negative
margins and a pathological nodal stage of N0 to N2. For
patients who received PORT, they had to be treated with
external beam radiation to the lung and received a
minimum dose of4500 cGy. We also excluded those for
whom laterality and chemotherapy use were not iden-
tiﬁed. We identiﬁed 3581 patients who met the study
criteria. In order to account for immortal time bias,10 we
also excluded 564 patients who survived <4 months,
resulting in a cohort of 3017 patients.
Clinical, pathological, and demographic details were
compared between patients who received PORT and
those who did not using the chi square, Fisher’s exact,
and Mann–Whitney tests where appropriate. The pri-
mary objective of this study was to determine whether
the delivery of PORT impacts OS. Kaplan–Meier analyses
of OS were performed comparing patients who received
PORT with those who did not. Because immortal timebias has been proposed to potentially impact survival
outcomes, we also repeated the analyses for patients
who survived <7 months to conﬁrm that there were not
signiﬁcant differences in our ﬁndings. Separate Kaplan–
Meier analyses were performed, stratifying patients by
pathologic N stage. This was performed because nodal
stage was noted to be a signiﬁcant metric in identifying
appropriate candidates for postoperative radiation in
the non-SCLC (NSCLC) setting.11–13 Multivariate Cox
regression was also stratiﬁed by N group in order to
determine the effect of covariates on survival. The
variables measured included the selection of PORT,
age group, race, sex, receipt of chemotherapy, year of
diagnosis, T grouping, and surgery type. The year of
diagnosis was included to account for the potential
beneﬁt of improved conformal radiation techniques.
Because the encoding of intensity-modulated radiation
(IMRT) was ﬁrst initiated in 2005 in the NCDB, we used
1998–2004 and 2005–2011 as the year of diagnosis
cutoff points. Data regarding local control and cause of
death are not available in the NCDB. Signiﬁcant values
were deﬁned as p < 0.05. Statistical analysis was per-
formed using SPSS software (version 21; IBM Inc,
Armonk, NY).
Results
Patient Characteristics
There were 3017 patients who met the inclusion
criteria. The most common surgical procedure was lo-
bectomy (70%) followed by sublobar resection (25%).
The median number of days from diagnosis to deﬁnitive
surgery was 20 days. Chemotherapy was delivered to
61.2% of patients at a median of 57 days from diagnosis.
With regard to PORT, 448 patients (14.8%) received
PORT to a median dose of 54 Gy. The median number of
days from diagnosis until receipt of radiation was 91
days. The median age was 68 years and the median
follow-up was 28.6 months. At last contact, 63.4% of
patients were dead. Additional details regarding patient
characteristics and comparisons between those who did
or did not receive PORT are available in Table 1.
Survival
Analyzing the entire cohort, OS was poorer in pa-
tients who received PORT (5-year OS 33.9% versus
40.6%; p ¼ 0.005). However, when analyzed by N stage
subgroup, differences emerged. The 5-year OS for path-
ologic N0 was 39.3% versus 46.3% (p ¼ 0.07; Fig. 1). For
pathologic N1 disease, the 5-year OS was 33.3% for
PORT versus 27.7% for no PORT (p ¼ 0.22; Fig. 2).
However, for pathologic N2 disease, the 5-year OS was
improved with the use of PORT (29.0% versus 18.6%;
p < 0.001; Fig. 3).
Figure 1. Kaplan–Meier curves for overall survival with and
without postoperative radiation therapy (PORT) for patients
with pathologic N0 disease (pN0).
Table 1. Patient Characteristics and Comparison Between
Those Receiving or Not Receiving Postoperative Radiation
No PORT PORT p Value
Age, y (median) 69 65 <0.001
Sex, n (%) 0.15
Male 1183 (46.0) 223 (49.8)
Female 1386 (54) 225 (50.2)
Race, n (%) 0.15
White 2363 (92) 422 (94.2)
African American 142 (5.5) 21 (4.7)
Other 64 (2.5) 5 (1.1)
Laterality, n (%) 0.14
Right 1431 (55.7) 232 (53.0)
Left 1138 (44.3) 216 (47.0)
Surgical procedure, n (%) <0.001
Sublobar resection 599 (23.3) 156 (34.8)
Lobectomy 1834 (71.4) 278 (62.1)
Pneumonectomy 136 (5.3) 14 (3.1)
Chemotherapy, n (%) <0.001
Yes 1415 (55.1) 431 (96.2)
No 1154 (44.9) 17 (3.8)
Pathologic N stage, n (%) <0.001
N0 1886 (73.4) 146 (32.6)
N1 469 (18.3) 134 (29.9)
N2 214 (8.3) 168 (37.5)
Pathologic T stage, n (%) <0.001
T1–2 2408 (93.7) 397 (88.6)
T3 71 (2.8) 26 (5.8)
T4 90 (3.5) 25 (5.6)
PORT, postoperative radiation.
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On multivariate analysis, age was a signiﬁcant pre-
dictor for decreased survival for all pathologic N stages
(Table 2). For N0 disease, lack of chemotherapy (hazard
ratio [HR] ¼ 1.18 [95% conﬁdence interval {CI}, 1.05–
1.33]; p ¼ 0.006) and PORT (HR ¼ 1.36 [95% CI, 1.09–
1.70]; p < 0.001) were associated with poorer survival.
Female sex (HR ¼ 0.77 [95% CI, 0.69–0.87]; p < 0.001)
and surgery with lobectomy or pneumonectomy were
associated with improved survival. For pathologic N1
disease, lack of chemotherapy administration was asso-
ciated with poorer survival (HR ¼ 1.62 [95% CI, 1.31–
2.01]; p < 0.001). PORT was not associated with any
survival differences (HR ¼ 1.01 [95% CI, 0.79–1.30]; p ¼
0.73). However, female sex was again strongly associated
with improved survival (HR ¼ 0.71 [95% CI, 0.59–0.86];
p < 0.001). For N2 disease, PORT was strongly associ-
ated with improved survival (HR ¼ 0.60 [95% CI, 0.45–
0.80]; p < 0.001) and female sex (HR ¼ 0.69 [95% CI,
0.54–0.88]; p ¼ 0.003. Additional details are available in
Table 2.
Discussion
In this large population-based analysis, we found that
the addition of PORT was overall detrimental to SCLCpatients who underwent complete surgical resection,
particularly in the large subgroup of patients with
pathologic N0 disease. However, in patients with path-
ologic N2 disease, PORT signiﬁcantly improved the ab-
solute 5-year OS by 10.4% from 18.6% to 29.0%, and
this advantage retained signiﬁcance on multivariable
analysis. There was no difference in survival detected
with or without PORT for patients with pathologic N1
disease.
Because of the rarity of patients presenting with
clinical stage T1–2, N0 disease, there are scarce data
regarding the optimal management of patients with
early-stage disease. Two older randomized trials did not
ﬁnd a beneﬁt to the addition of surgery to multimodality
management for LS-SCLC.3,4 However, patients with
early-stage disease were underrepresented in these tri-
als. Findings from single-institution series have sug-
gested that surgery for select patients is efﬁcacious, with
5-year OS ranging from 52% to 58% for stage I dis-
ease.6,14–18 Analyses of population-based datasets have
provided additional support for the use of operative
management. An analysis of the SEER database con-
ducted by our group reported a 5-year OS of 52.6% in
patients with stage I disease who underwent lobectomy.5
A separate SEER study by Yu et al.16 reported a com-
parable 5-year OS of 50% for these patients. Although
Figure 3. Kaplan–Meier curves for overall survival with and
without postoperative radiation therapy (PORT) for patients
with pathologic N2 disease (pN2).
Figure 2. Kaplan–Meier curves for overall survival with and
without postoperative radiation therapy (PORT) for patients
with pathologic N1 disease (pN1).
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SCLC, National Comprehensive Cancer Network (NCCN)
guidelines support the use of lobectomy with medias-
tinal lymph node evaluation as a treatment option for
patients with clinical stage T1–2, N0 disease7 based on
these data.
To our knowledge, there are no prospective studies
addressing the role of PORT in patients with surgically
resected SCLC. In the aforementioned SEER analysis by
Yu et al.,16 the authors reported a nonsigniﬁcant trend
toward improved survival with the use of PORT after
lobectomy (5-year OS 57.1% with PORT versus 49.1%
without PORT; p ¼ 0.09). Conversely, a SEER analysis by
Varlotto et al.17 found a nonsigniﬁcant decrease in sur-
vival with the use of adjuvant PORT after lobectomy
(median survival 37 months with PORT versus 50
months without PORT; p ¼ 0.201) and after sublobar
resection (median survival 28 months with PORT versus
30 months without PORT; p ¼ 0.585). These ﬁndings
indicate that PORT is likely not beneﬁcial for all patients
receiving surgical resection.
However, several groups have further analyzed PORT
outcomes based on the extent of nodal disease. In the
SEER analysis by Schreiber et al.,5 the authors found that
while there was no signiﬁcant difference in OS with orwithout PORT in patients with pathologic N0 or N1
disease, there was a signiﬁcant improvement in survival
with the addition of PORT in the subgroup of patients
with pathologic N2 disease (median survival 22 months
with PORT versus 16 months without PORT; p ¼ 0.011).
Liu et al.9 recently conducted a single-institution retro-
spective review of 143 patients with completely resected
SCLC. For the entire cohort, PORT had no signiﬁcant
impact on survival, with a median survival of 40 months
in patients with PORT versus 27 months without PORT
(p ¼ 0.26). On subgroup analysis, PORT led to signiﬁcant
improvements in both OS and locoregional control in
patients with pathologic node-positive disease. For pa-
tients with N1 disease, the median survival was 40
months with PORT and 14 months without PORT (p ¼
0.032). For patients with N2 disease, the median survival
was 35 months with PORT and 17 months without PORT
(p ¼ 0.04).
In this study from the NCDB, we found that PORT led
to a survival detriment on multivariate analysis in pa-
tients with pathologic N0 disease (5-year OS 34.5% with
PORT versus 44.1% without PORT; p ¼ 0.07; HR ¼ 1.36
[95% CI, 1.09–1.70]; p < 0.001). There were no survival
difference in those with pathologic N1 disease (5-year
OS 33.3% with PORT versus 27.7% without PORT;
Table 2. Multivariate Analysis for Patients with Pathologic N0, N1, and N2 Disease
Variable
pN0 pN1 pN2
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Age (y)
60 1 1 1
61–70 1.55 (1.35–1.77) <0.001 1.37 (1.11–1.70) 0.004 1.78 (1.36–2.32) <0.001
>70 2.08 (1.77–2.45) <0.001 1.58 (1.19–2.10) 0.002 1.95 (1.37–2.78) <0.001
Race
White 1 1 1
African American 0.83 (0.63–1.08) 0.17 0.61 (0.36–1.03) 0.06 0.52 (0.30–0.90) 0.02
Other 1.07 (0.74–1.55) 0.73 1.46 (0.75–2.86) 0.27 0.55 (0.22–1.36) 0.20
Year of diagnosis
1998–2004 1 1 1
2005–2011 1.00 (0.89–1.13) 0.99 1.14 (0.93–1.39) 0.20 0.84 (0.65–1.09) 0.19
Chemotherapy
Yes 1 1 1
No 1.18 (1.05–1.33) 0.006 1.62 (1.31–2.01) <0.001 0.80 (0.59–1.09) 0.16
Surgery type
Sublobar resection 1 1 1
Lobectomy 0.74 (0.65–0.85) <0.001 0.85 (0.65–1.10) 0.22 0.91 (0.71–1.18) 0.49
Pneumonectomy 0.63 (0.42–0.94) 0.02 0.93 (0.64–1.37) 0.73 0.79 (0.49–1.28) 0.34
Postoperative radiation
No 1 1 1
Yes 1.36 (1.09–1.70) <0.001 1.01 (0.79–1.30) 0.92 0.60 (0.45–0.80) <0.001
Sex
Male 1 1 1
Female 0.77 (0.69–0.87) <0.001 0.71 (0.59–0.86) <0.001 0.69 (0.54–0.88) 0.003
T stage
T1–2 1 1 1
T3 1.74 (1.23–2.46) 0.002 1.32 (0.96–1.83) 0.09 1.12 (0.68–1.86) 0.66
T4 1.86 (1.23–2.83) 0.004 1.14 (0.93–1.39) 0.20 1.14 (0.76–1.70) 0.54
CI, conﬁdence interval; HR, hazard ratio.
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ciated with PORT in patients with pathologic N2 disease
(5-year OS 29.0% with PORT versus 18.6% without
PORT; p < 0.001). These ﬁndings are similar to the
SEER-based analysis by our group and interestingly,
parallel the more robust NSCLC literature on PORT. In
their most recent meta-analysis, the PORT Meta-analysis
Trialists Group reported a deleterious effect of PORT
for NSCLC patients with pathologic N0–1 disease,
whereas there was no signiﬁcant impact for patients
with pathologic N2 disease.11 A secondary analysis of the
Adjuvant Navelbine International Trialist Association
randomized study of adjuvant chemotherapy found a
survival detriment for PORT in patients with pathologic
N1 disease who were receiving adjuvant chemo-
therapy.12 However, PORT signiﬁcantly improved sur-
vival in patients with pathologic N1 disease who were
not receiving adjuvant chemotherapy and in all patients
with pathologic N2 disease, regardless of receipt of
chemotherapy. A recently published NCDB analysis
conﬁrmed a survival beneﬁt for PORT in pathologic N2
NSCLC patients treated with adjuvant chemotherapy(5-year OS 39.3% with PORT versus 34.8% without
PORT; p ¼ 0.014).13
We noted several other interesting ﬁndings on
multivariate analysis. First, we found that more exten-
sive resection was associated with improved survival for
patients with pathologic N0 disease (HR ¼ 0.74, p <
0.001 for lobectomy versus sublobar resection and HR ¼
0.63, p ¼ 0.02 for pneumonectomy versus sublobar
resection). In a SEER analysis of patients with stage I/II
SCLC, Weksler et al.18 similarly reported that lobectomy
was associated with improved survival compared to
wedge resection (HR ¼ 0.799, p ¼ 0.038). When
considered together, these ﬁndings suggest that sublobar
resection may be inadequate treatment.
We also found that lack of chemotherapy receipt was
associated with poorer survival for patients with path-
ologic N0 (HR ¼ 1.18 [95% CI, 1.05–1.33]; p ¼ 0.006)
and N1 patients (HR ¼ 1.62 [95% CI, 1.31–2.01]; p <
0.001), but there was no clear impact on survival for
patients with pathologic N2 disease (HR ¼ 0.80, p ¼
0.16). This may suggest the greater impact of locore-
gional control on survival in patients with N2 disease.
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gional control with the addition of PORT in patients with
N2 disease compared to N1 disease (3-year locoregional
relapse 0% with PORT versus 14.3% without PORT for
N1 patients and 4.2% with PORT versus 56.6% without
PORT). Unfortunately, data on locoregional control are
not available in the NCDB, and these ﬁndings cannot be
conﬁrmed in our analysis. In addition, our analysis may
have been underpowered to detect a survival difference
because there were few patients with N2 disease that did
not receive chemotherapy. It should also be noted that
these ﬁndings may be related to a selection bias that is
unmeasured with the NCDB. For example, we found that
while only 55.1% of patients not receiving PORT
received chemotherapy, nearly all (96.1%) patients who
received PORT also received chemotherapy. It is unclear
what underlying factors determined whether or not
adjuvant therapy was given, but it is clear that the
clinicopathologic concerns that led to the delivery of
PORT also inﬂuenced chemotherapy use, which may
have led to a skewed study cohort when analyzing the
impact of chemotherapy on survival.
We also found that female sex was strongly associ-
ated with improved survival across all N stage sub-
groups, which is in agreement with ﬁndings from
previously published studies. A single-institution review
by Videtic et al.19 reported that women had better sur-
vival than men (5-year OS 12.5% versus 2.5%; p ¼ 0.07),
independent of other treatment variables, including
smoking cessation and radiation treatment in-
terruptions. The authors postulated that the mechanism
for improved survival in women involves inherent dif-
ferences in either tumor biology or the hormonal milieu
rather than behavioral differences. Additional studies are
needed to fully elucidate the underlying mechanism of
this observation.
Because the NCDB did not begin encoding the use of
IMRT until 2005, we stratiﬁed patients by the year of
diagnosis using 2005 as a cutoff as a surrogate to assess
the potential impact of conformal radiation techniques
on survival within our study population. On multivariate
analysis, the year of diagnosis had no signiﬁcant impact
on survival. Previous studies have shown a dosimetric
advantage of IMRT over conventional radiation in
reducing the lung V20 (volume of lung receiving at least
20 Gy), potentially reducing toxicity.20 Previous
population-based studies have suggested that this dosi-
metric beneﬁt translates into improvements in clinical
outcomes for patients with locally advanced NSCLC.21,22
Whether this beneﬁt exists for patients with SCLC or in
the postoperative setting remains unknown.
A major limitation of this study is the lack of cancer-
speciﬁc survival data. Although most patients with SCLC
are likely to die from their disease, other-cause mortalitymay be a factor, particularly for older patients with other
comorbidities. A second limitation is the detailed infor-
mation regarding chemotherapeutic agents used as well
as the sequencing of therapy. The median number of
days from diagnosis to surgery (19 days), chemotherapy
(56 days), and radiation therapy (89.5 days) suggest that
most patients underwent surgery ﬁrst followed
sequentially by chemotherapy and PORT. A third limi-
tation is the lack of central pathologic review in the
current analysis. Because of this lack of central patho-
logic conﬁrmation, we are unable to ascertain whether
some of the patients included in this study were mis-
identiﬁed as having SCLC or whether they may have had
a tumor with mixed small cell and NSCLC components,
which might exhibit better outcomes than a conﬁrmed
diagnosis of pure SCLC. Fourth, the NCDB does not
encode data on postoperative complications, which
could potentially impact survival and the receipt of
adjuvant therapies. A large number of patients (n ¼ 564)
were excluded from this study to account for immortal
time bias and its impact on the receipt of PORT and the
survival outcomes. However, we were unable to assess
whether these patients died from early progression or
from complications related to their surgery. Finally,
because of the limitations of our dataset, it is unclear if
there were any selection biases in patients receiving
surgery, PORT, or chemotherapy in regards to perfor-
mance status, access to health care, or other health-
related issues.
In conclusion, this study is the largest to date specif-
ically addressing the role of PORT in limited-stage SCLC
patients undergoing complete surgical resection. We
report that PORT appears to adversely affect survival in
patients with pathologic N0 disease, has no impact on
survival in patients with pathologic N1 disease, and
signiﬁcantly improves survival in patientswith pathologic
N2 disease. These ﬁndings support a role for adjuvant
PORT only in patients with pathologic N2 disease.References
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